BC Week In Review | Aug 3, 2015
Clinical News

P2B001: Phase IIb data

A double-blind, U.S. and Israeli Phase IIb trial in 149 patients with early stage PD showed that once-daily low- and high-dose oral P2B001 each met the primary endpoint of reducing UPDRS Part I, II and...
BC Week In Review | Mar 9, 2015
Clinical News

P2B001: Completed Phase IIb enrollment

Pharma Two completed enrollment of 149 patients in a double-blind, placebo-controlled, U.S. and Israeli Phase IIb trial evaluating 2 doses of oral P2B001 once daily for 12 weeks. The company is developing the product under...
BC Week In Review | Mar 24, 2014
Clinical News

P2B001: Phase IIb started

Pharma Two began a double-blind, placebo-controlled, U.S. and Israeli Phase IIb trial to evaluate 2 doses of oral P2B001 once daily for 12 weeks in 150 patients with early PD. The company is developing the...
BC Week In Review | Jun 24, 2013
Company News

Knopp Biosciences, Prize4Life Inc. neurology news

Knopp will donate de-identified clinical data from 468 patients in the placebo arm in the Phase III EMPOWER trial evaluating dexpramipexole in amyotrophic lateral sclerosis to not-for-profit Prize4Life's PRO-ACT database. Knopp also plans to contribute...
BC Week In Review | Mar 11, 2013
Company News

Biogen Idec, Knopp Biosciences neurology news

Knopp filed suit in the U.S. District Court for the District of Massachusetts against partner Biogen Idec seeking the return of "invaluable" biosamples from patients with amyotrophic lateral sclerosis. The company is also seeking a...
BC Extra | Mar 9, 2013
Company News

Knopp suing Biogen over ALS biosamples

Knopp Biosciences LLC (Pittsburgh, Pa.) filed suit in the U.S. District Court for the District of Massachusetts against partner Biogen Idec Inc. (NASDAQ:BIIB) seeking the return of "invaluable" biosamples from patients with amyotrophic lateral sclerosis....
BC Week In Review | Jan 7, 2013
Clinical News

Dexpramipexole: Development discontinued

Biogen Idec discontinued development of dexpramipexole after top-line data from the double-blind, international Phase III EMPOWER trial in 943 ALS patients showed that twice-daily 150 mg dexpramipexole for up to 18 months missed the primary...
BC Extra | Jan 4, 2013
Top Story

BIIB discontinues dexpramipexole for ALS

Biogen Idec Inc. (NASDAQ:BIIB) fell $2.14 to $147.86 on Thursday after discontinuing development of dexpramipexole for amyotrophic lateral sclerosis (ALS). The stock move translates to a loss in market cap of $506.3 million for a...
BC Week In Review | Oct 1, 2012
Clinical News

Mirapexin pramipexole regulatory update

FDA issued a drug safety communication warning of a possible risk of heart failure in patients taking Boehringer's Mirapex pramipexole to treat Parkinson's disease and primary restless leg syndrome (RLS). FDA said the alert is...
BioCentury | Oct 1, 2012
Finance

4Q Financial Markets Preview: Bellwether's ball

For only the second time since 2000, the BioCentury 100 index has matched or beaten the S&P 500 for four consecutive quarters, with most of the gains driven by the bellwether names. Buysiders are cautiously...
Items per page:
1 - 10 of 69